Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06799065 | RECRUITING | Advanced Solid Tumors

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Sponsor:

Accent Therapeutics

Brief Summary:

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

Condition or disease

Advanced Solid Tumors

Breast Cancer Recurrent

Ovarian Cancer

High-grade Serous Ovarian Carcinoma

Triple Negative Breast Cancer

Intervention/treatment

ATX-295

Phase

PHASE1

Detailed Description:

ATX-295 is an oral drug that inhibits a protein called KIF18A, an adenosine triphosphate (ATP)-dependent, plus end-directed mitotic kinesin. KIF18A facilitates chromosomal alignment and spindle microtubule dynamics during mitosis in certain advanced solid tumors. ATX-295 has been shown preclinically to induce robust anti-tumor activity of a variety of different solid tumors, including high-grade serious ovarian cancer and triple negative breast cancer. This is a first-in-human, Phase 1, open-label, single-arm, dose-escalation and Simon 2-Stage expansion study to evaluate the safety profile of ATX-295 and determine the recommended phase 2 dose (RP2D). In addition, the study aims to characterize the PK, PD, and preliminary anti-tumor activity of orally administered ATX-295. Exploratory objectives include examination of biomarker responses in relationship to ATX-295 exposure. Patients with locally advanced or metastatic solid tumors will be enrolled to preliminarily assess the anti-tumor effect, and further examine the safety and PK of ATX-295 at the RP2D.

Study Type : INTERVENTIONAL
Estimated Enrollment : 65 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer
Actual Study Start Date : 2025-03-21
Estimated Primary Completion Date : 2027-04-30
Estimated Study Completion Date : 2027-08-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Key Inclusion Criteria
  • * Patients with histologically confirmed solid tumors who have locally recurrent or metastatic disease, including HGSOC
  • * Refractory to or relapsed after all standard therapies with proven clinical benefit, unless as deemed by the Investigator, the subject is not a candidate for standard treatment, there is no standard treatment, or the subject refuses standard treatment after expressing an understanding of all available therapies with proven clinical benefit
  • * For the expansion cohorts, participants must have histological confirmation of HGSOC and be determined to be platinum-resistant, platinum-refractory, or platinum-intolerant
  • * There is no limit to the number of prior treatment regimens
  • * Have measurable or evaluable disease
  • * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Key Exclusion Criteria
    • * Clinically unstable central nervous system (CNS) tumors or brain metastasis
    • * Any other concurrent anti-cancer treatment, except for hormonal blockade
    • * Has undergone a major surgery within 3 weeks of starting study treatment
    • * Medical issue that limits oral ingestion or impairment of gastrointestinal function that is expected to significantly reduce the absorption of ATX-295, however participants with a functioning distal ileostomy or colostomy may be permitted on trial
    • * Clinically significant (ie, active) or uncontrolled cardiovascular disease
    • * Need to use proton pump inhibitors on study or H2-receptor antagonists for the dose escalation portion of the study.
    • * Unable to transition off strong or moderate CYP3A4 inhibitors or strong inducers
    • * Pregnancy or intent to breastfeed or conceive a child within the projected duration of treatment
    • Other inclusion and exclusion criteria as defined in the study protocol
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Location Details

NCT06799065

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Texas

MD Anderson Cancer Center

Houston, Texas, United States, 77030

RECRUITING

United States, Texas

NEXT Oncology

San Antonio, Texas, United States, 78229